论文部分内容阅读
目的探究液基超薄细胞学检查(TCT)联合高危型人乳头瘤病毒脱氧核糖核酸(HPV-DNA)检测对宫颈癌筛查的应用效果。方法 1651例宫颈癌筛查者分别采用TCT、高危型HPV-DNA进行筛查,并对检测呈阳性者进行病理学检查,对比单纯TCT、TCT+高危型HPV-DNA联合检查的阳性符合率。结果 1651例宫颈癌筛查者经TCT阳性筛查率为20.4%(337/1651),TCT+高危型HPV-DNA阳性筛查率为26.7%(440/1651);阴道镜活检675例,病理阳性425例;TCT阳性符合率79.3%低于TCT+高危型HPV-DNA阳性符合率96.6%(P<0.05)。结论对宫颈癌筛查者行TCT+高危型HPV-DNA联合筛查对早期、准确诊断宫颈病变有重要的临床价值,值得应用。
Objective To investigate the effect of TCT combined with high-risk human papillomavirus (HPV) DNA testing on cervical cancer screening. Methods Totally 1651 cervical cancer screening patients were screened by TCT and high-risk HPV-DNA respectively. The positive rates of TCT and TCT + high-risk HPV-DNA combined tests were also compared. Results The positive screening rate of TCT + high-risk HPV-DNA in 1651 cervical cancer screening patients was 20.4% (337/1651), the positive screening rate was 26.7% (440/1651), the colposcopy biopsy was 675, 425 cases; the positive coincidence rate of TCT was 79.3%, lower than that of TCT + high-risk HPV-DNA positive 96.6% (P <0.05). Conclusion The screening of cervical cancer screening TCT + high-risk HPV-DNA screening of early, accurate diagnosis of cervical lesions have important clinical value, it is worth applying.